echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Looking at how the pharmaceutical industry in the post-epidemic era will innovate and transform from the guiding principles of anti-tumor drugs

    Looking at how the pharmaceutical industry in the post-epidemic era will innovate and transform from the guiding principles of anti-tumor drugs

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    As the new crown epidemic becomes normalized, market sentiment in the pharmaceutical sector has gradually returned to rationality
    .
    Since the Drug Evaluation Center of the National Medical Products Administration issued the "Clinical Value-Oriented Clinical Research and Development Guidelines for Anti-tumor Drugs" (draft for comments) on July 2, the pharmaceutical sector began to fluctuate and decline as a whole, and entered the medical insurance in November.
    Negotiations, on the 19th, the Review Center officially issued the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value".
    After the policy was implemented, the trend of the medical sector finally began to pick up

    .

    What is the "magic power" of a guidance document?

    What is the "magic power" of a guidance document?

    The "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Values" (hereinafter referred to as "Guiding Principles for Anti-tumor Drugs") emphasizes that the development of new drugs should be based on patient needs and clinical value-oriented
    .
    This principle puts forward higher requirements for the research and development of innovative drugs, and aims to realize the fundamental value of new drug research and development—solving clinical needs and maximizing patient benefits

    .
    The research and development of innovative drugs has the characteristics of high risk, high investment and high return, and has strong technical barriers

    .
    The "Guiding Principles of Anti-tumor Drugs" will make the Matthew effect of innovative drug research and development more prominent.
    Head drugs with rich pipelines and large R&D investment will stabilize and occupy a strong position, while pharmaceutical companies lacking innovative capabilities and weak R&D will face huge challenges.
    This is undoubtedly It will promote the gradual transformation of most pharmaceutical companies in China from me-too to me-better or completely independent innovative drugs

    .

    Stones from other mountains can be used for jade, how to implement the guiding principles of anti-tumor drugs?

    Stones from other mountains can be used for jade, how to implement the guiding principles of anti-tumor drugs?

    Looking at the new drug approvals in the first three quarters of 2021 in Europe and the United States, the US FDA and EU EMA have reviewed and approved a total of 27 new anti-tumor drugs
    .
    Stones from other mountains can be used to attack jade.
    Next, take the new anti-tumor drugs approved in Europe and the United States as an example to specifically interpret the five new drug R&D requirements in China's "Guiding Principles of Anti-tumor Drugs" that are oriented to patient needs

    .

    0 1.
    Strengthen mechanism research

    0 1.
    Strengthen mechanism research

    The US FDA accelerated the approval of Amgen’s KRASG12C inhibitor Lumakras on May 28 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRASG12C mutations who have received at least one systemic treatment in the past
    .
    Lumakras is the world's first drugged KRASG12C inhibitor after more than 40 years of research on KRAS mutant oncoproteins

    .
    Merck’s new anti-tumor drug, Welireg, is the first HIF-2α inhibitor therapy, and is the first and only drug approved for the treatment of Hipper Lindau syndrome (VHL) disease-related cancers.
    The related biological research is in In 2019, he won the Nobel Prize in Physiology or Medicine

    .

    China's "Guiding Principles of Anti-tumor Drugs " clearly proposes that basic research and drug action mechanism innovation are the fundamental driving force for drug research and development
    .
    At the beginning of drug research and development, basic research on the mechanism of tumor occurrence and development should be strengthened, and the research on the mechanism of drug action should be strengthened at the same time.
    Through breakthroughs and innovation, drug design is optimized, and new treatment methods are developed to continuously meet the treatment needs of tumor patients

    .

    Basic research and innovation in the mechanism of drug action are the fundamental driving force for the advancement of drug research and development
    .
    At the beginning of drug research and development, basic research on the mechanism of tumor occurrence and development should be strengthened, and the research on the mechanism of drug action should be strengthened at the same time.
    Through breakthroughs and innovation, drug design is optimized, and new treatment methods are developed to continuously meet the treatment needs of tumor patients

    .

    0 2.
    Improve precision treatment

    0 2.
    Improve precision treatment

    With the rapid development of biotechnology in the medical field and the continuous in-depth research on tumor pathogenesis, tumor diagnosis and treatment have been transformed into precision medicine
    .
    In the first three quarters of 2021, Europe and the United States have approved a number of new anti-tumor drugs for precision treatment

    .

    The targeted anti-tumor drug Teppetko is used to treat adult patients with advanced non-small cell lung cancer (NSCLC) carrying the MET gene exon 14 skipping change (METex14skipping).
    It is the first approved treatment in the world for the treatment of MET gene change Oral MET inhibitor for advanced NSCLC patients

    .
    Eli Lilly’s Retsevmo is used to treat advanced lung and thyroid cancer that are positive for RET fusion

    .
    Pemazyre is the first targeted therapy to treat patients with locally advanced or metastatic cholangiocarcinoma who have undergone at least one systemic therapy and have relapsed or refractory disease, FGFR2 fusion or rearrangement, and unresectable locally advanced or metastatic cholangiocarcinoma

    .
    The new anti-tumor drug of GlaxoSmithKline (GSK) anti-PD-1 therapy Jemperli is used to treat patients with disease progression, mismatch repair defects (dMMR) recurrent or advanced endometrial cancer during or after platinum-containing chemotherapy.
    It is also approved by the FDA and EMA approved

    .
    Johnson & Johnson's (JNJ) EGFR-MET bispecific antibody Rybrevant is used to treat adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed after receiving platinum-containing chemotherapy and have a positive mutation in exon 20 of the EGFR gene.
    The first targeted therapy approved for the treatment of EGFR exon 20 insertion mutation-positive NSCLC

    .
    Takeda's innovative lung cancer drug, Exkivity, is used to treat disease progression during or after previous platinum-containing chemotherapy.
    The FDA-approved detection method is confirmed to carry the epidermal growth factor receptor (EGFR) exon 20 insertion mutation (EGFRex20ins).
    ) Adult patients with locally advanced or metastatic non-small cell lung cancer

    .

    China’s "Guiding Principles of Anti-tumor Drugs " emphasizes that in the process of anti-tumor drug research and development, attention should be paid to and continuous improvement of the matching degree between patients and therapeutic drugs, and continuously improve the accuracy of anti-tumor treatment, so that cancer patients can receive more suitable for them.
    Therapeutic drugs

    .

    It is emphasized that in the process of anti-tumor drug development, attention and continuous improvement of the matching degree between patients and treatment drugs should be paid to continuously improve the accuracy of anti-tumor treatment so that cancer patients can receive treatment drugs that are more suitable for them
    .

    0 3.
    Pay
    attention to the dynamic changes of treatment needs

    0 3.
    Pay
    attention to the dynamic changes of treatment needs

    With the development of targeted therapies, anti-tumor treatments have become more and more precise, and the effectiveness of anti-tumor drug treatments has gradually improved, but the treatment needs of tumor patients are always in dynamic changes
    .

    A new generation of oral PI3Kδ/CK1-ε dual inhibitor Ukoniq is used to treat patients who have received at least one relapsed or refractory marginal zone lymphoma (MZL) based on an anti-CD20 regimen or who have received at least 3 systemic therapies.
    Or refractory follicular lymphoma (FL) adult patients

    .
    Nexpovio was approved by EMA to be used in combination with dexamethasone to treat at least two proteasome inhibitors (PI), two immunosuppressive agents (IMiD), and one anti-CD38 monoclonal antibody.
    Adult patients with refractory, relapsed or refractory multiple myeloma (RRMM) whose disease progressed when receiving the last therapy

    .
    Jazz Pharmaceuticals’ Rylaze has been approved by the US FDA for the treatment of children and adults aged 1 month and older who are allergic to E.
    coli-derived asparaginase

    .
    Tivdak is used to treat adult patients with recurrent or metastatic cervical cancer who have progressed during chemotherapy or after chemotherapy to deal with the current situation that once cervical cancer recurs or metastasizes, clinical treatment options are very limited

    .
    Minjuvi is used in combination with lenalidomide and then tafasitamab as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/rDLBCL) who are not suitable for autologous stem cell transplantation (ASCT)

    .

    China's "Guiding Principles of Anti-tumor Drugs" also clearly proposes to always pay attention to the changes in patients' treatment needs, and constantly explore the unmet clinical needs of anti-tumor patients
    .

    Always pay attention to the changes in the treatment needs of patients, and constantly explore the unmet clinical needs of anti-tumor patients
    .

    0 4.
    Continuously improve drug safety

    0 4.
    Continuously improve drug safety

    Breyanzi was originally developed by Juno as a CAR-T cell therapy targeting CD19 antigen
    .
    Compared with other CAR-T therapies already on the market, Breyanzi has the best safety data.
    The ratio of CD8-positive and CD4-positive T cells is 1:1, which can better control the side effects of cell therapy

    .
    The FDA-approved Cosela is the world's first and only bone marrow protective therapy that can reduce the incidence of chemotherapy-induced bone marrow suppression, and can provide bone marrow protection for ES-SCLC patients undergoing chemotherapy

    .
    It can reduce the incidence and duration of severe neutropenia and anemia, and reduce the need for rescue interventions such as growth factors and red blood cell transfusion

    .
    China’s "Guiding Principles of Anti-tumor Drugs " proposes that
    in the development of anti-tumor drugs, attention should be paid to the safety of tumor patients, especially the increasing demand and expectations for the safety of long-term drugs, which will increase and continuously improve the anti-tumor drugs Security is an important research direction
    .

    In the research and development of anti-tumor drugs, attention should be paid to the safety of tumor patients, especially the increasing demand and expectations for the safety of long-term drugs.
    Improving and continuously improving the safety of anti-tumor drugs is an important research and development direction

    .

    0 5.
    Improve treatment experience and convenience

    0 5.
    Improve treatment experience and convenience

    In March of this year, the US FDA approved Abecma for the treatment of adult patients with relapsed and refractory multiple myeloma (R/RMM)
    .
    Abecma is the world's first BCMA-oriented CAR-T cell therapy on the market

    .
    The approval of Abecma on the market will provide such patients with a new, effective, and personalized treatment plan that can achieve rapid, deep, and lasting relief with only one infusion

    .
    In addition to the development of long-acting preparations, other improved routes of administration given in China's "Guiding Principles of Anti-tumor Drugs" include the development of subcutaneous preparations and oral preparations to
    improve the convenience of patient treatment; reduce the frequency of administration and help reduce patient treatment Burden
    .

    Improve the convenience of treatment for patients; reduce the frequency of administration, which helps reduce the burden of treatment for patients
    .

    Innovation is a long-term process that cannot be accomplished overnight
    .
    China's pharmaceutical innovation has a good start, but the road ahead is still long.
    What is certain is that the direction of China's vigorous development of innovative drugs is very clear, strengthen the integration of research, industry and academia, fully link the academic and business circles, and open up the source of innovation and commercialization to meet the needs of patients.
    As the core, with clinical application as the purpose, to promote the gradual formation and improvement of the industrialization chain

    .
    The pharmaceutical industry is closely related to people's lives and is an everlasting sunrise industry.
    Higher innovation requirements will only accelerate China's progress towards an era of innovation in the pharmaceutical industry and usher in a golden age of pharmaceutical innovation

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.